Can two drugs beat opioid relapse? new trial aims to find out

NCT ID NCT05011266

Recruiting now Disease control Sponsor: New York State Psychiatric Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding buprenorphine (a partial opioid) to the standard shot XR-naltrexone helps people with opioid use disorder stay in treatment and avoid relapse. 180 adults will receive either the combo or a placebo for 24 weeks. The goal is to see if the combo improves retention, reduces cravings, and boosts mood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: buprenorphine/naloxone (Zubsolv) combined with extended-release naltrexone
What this could lead to: If it works, this combination could help people with opioid use disorder stay in treatment longer and reduce cravings and relapse.
What could go wrong: This is a mid-stage trial with only 180 participants, so results may not apply to everyone. Adding buprenorphine to naltrexone is a new approach and may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-USE DISORDER

Contacts and locations

Locations

Avery Road Treatment Center (ARTC)
RECRUITING

Rockville, Maryland, 20853, United States
Stars/Nyspi
TERMINATED

New York, New York, 10019, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.